NCT06132880View on ClinicalTrials.gov

Effects of Human Urinary Kallidinogenase on Early Improvement and Functional Outcomes in Acute Ischemic Stroke (TK-SPEED)

NANot yet recruitingINTERVENTIONAL

Enrollment

540

Participants

Timeline

Start Date

December 14, 2023

Primary Completion Date

August 28, 2026

Study Completion Date

December 31, 2026

Conditions

Acute Ischemic StrokeFunctional Outcomes

Interventions

DRUG

Human Urinary Kallidinogenase

Intravenous injections of urinary kallidinogenase (0.15 peptide nucleic acids (PNA) in 0.9% NaCl) intravenous drip QD for 10 days.

OTHER

Clinical Routine Treatment

Conventional therapy of acute ischemic stroke after based on Chinese guidelines

All Listed Sponsors

collaborator

Peking University People's Hospital

OTHER

lead

Beijing Tsinghua Chang Gung Hospital

OTHER

NCT06132880 - Effects of Human Urinary Kallidinogenase on Early Improvement and Functional Outcomes in Acute Ischemic Stroke (TK-SPEED) | Biotech Hunter | Biotech Hunter